AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1618486 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy
Number of subjects: 91
Study 1618486 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 91
Study 6385259 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (60 mg/m2 every 3 weeks)
Number of subjects: 59
Study 6385259 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (12 mg/m2 every 3 weeks)
Number of subjects: 59
Study 6385259 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin or Mitoxantrone (as secondary therapy)
Number of subjects: 59
Study 6385259 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 59
Study 6385259 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 59
Study 31797721 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement
Number of subjects: 18
Study 29848962 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried apples + rice (DApp + R)
Number of subjects: 11
Study 29848962 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meals (DF + R + A)
Number of subjects: 11
Study 29848962 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried fruits (DApp, DJ, Ra, DApr)
Number of subjects: 11
Study 29175841 — intervention group
Group type: EXPERIMENTAL
Intervention: Littlewoods forceps
Number of subjects: 100
Study 29175841 — intervention group
Group type: COMPARATOR
Intervention: Single-toothed tenaculum forceps
Number of subjects: 100
Study 29175841 — intervention group
Group type: EXPERIMENTAL
Intervention: Both forceps
Number of subjects: 100
Study 24744309 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-AGE diet
Number of subjects: 24
Study 24744309 — intervention group
Group type: COMPARATOR
Intervention: High-AGE diet
Number of subjects: 24
Study 22709418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral phenylephrine 1.5% (group 1)
Number of subjects: 42
Study 22709418 — intervention group
Group type: COMPARATOR
Intervention: Balanced saline solution (group 2)
Number of subjects: 42
Study 19814625 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 19814625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17686111 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray 110 microg
Number of subjects: 285
Study 17686111 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 285
Study 16327499 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LPS)
Number of subjects: 517
Study 16327499 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 517
Study 11931674 — intervention group
Group type: COMPARATOR
Intervention: Social phobics during the social conversation task
Number of subjects: 54
Study 11931674 — intervention group
Group type: COMPARATOR
Intervention: Clinically anxious group during the imagery task
Number of subjects: 54
Study 11931674 — intervention group
Group type: COMPARATOR
Intervention: Both clinical groups during the social conversation task
Number of subjects: 54
Study 11931674 — intervention group
Group type: COMPARATOR
Intervention: Both clinical groups during the imagery task
Number of subjects: 54
Study 9814616 — intervention group
Group type: EXPERIMENTAL
Intervention: DCLHb 25 mg/kg
Number of subjects: 53
Study 9814616 — intervention group
Group type: EXPERIMENTAL
Intervention: DCLHb 50 mg/kg
Number of subjects: 53
Study 9814616 — intervention group
Group type: EXPERIMENTAL
Intervention: DCLHb 100 mg/kg
Number of subjects: 53
Study 9814616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 7659434 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant-other version of the WHYMPI scales
Number of subjects: 0
Study 2642329 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir (800 mg) daily, taken twice daily
Number of subjects: 261
Study 2642329 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 261
Study 135666 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin alone (60 mg/m2 intravenously every 3 weeks)
Number of subjects: 31
Study 135666 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin plus streptozotocin (adriamycin 60 mg/m2 every 3 weeks + streptozotocin 500 mg/m2/day intravenously for 5 days every 3 weeks)
Number of subjects: 31
Study 135666 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin plus streptozotocin
Number of subjects: 31
Study 31586368 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-help program SaveMySkin (12-week program based on cognitive-behavioral therapy)
Number of subjects: 133
Study 31586368 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 133
Study 29112155 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee venom acupuncture (BVA)
Number of subjects: 54
Study 29112155 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 54
Study 25705815 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up telephone call by a senior orthopaedic nurse
Number of subjects: 219
Study 25705815 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 219
Study 22568471 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of DHA supplementation
Number of subjects: 21
Study 22568471 — intervention group
Group type: COMPARATOR
Intervention: Placebo soy oil
Number of subjects: 21
Study 22012833 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (2.5 μg/kg/min) administered postoperatively for 2 days
Number of subjects: 20
Study 22012833 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 20
Study 22012833 — intervention group
Group type: COMPARATOR
Intervention: Pancreaticoduodenectomy group (C)
Number of subjects: 20
Study 18176855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 10
Study 18176855 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 10
Study 15944424 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 351
Study 15944424 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 351
Study 12420901 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving treatment
Number of subjects: 0
Study 12420901 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant medication
Number of subjects: 0
Study 10340237 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping strategies
Number of subjects: 43
Study 10340237 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective representation of body image
Number of subjects: 43
Study 8942509 — intervention group
Group type: EXPERIMENTAL
Intervention: M-cup vacuum extractor cup
Number of subjects: 637
Study 8942509 — intervention group
Group type: COMPARATOR
Intervention: Obstetric forceps
Number of subjects: 637
Study 2018732 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid creams (four types representative of potency groups)
Number of subjects: 6
Study 2018732 — intervention group
Group type: COMPARATOR
Intervention: Base cream (control)
Number of subjects: 6
Study 6605681 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenbufen (1,000 mg a day)
Number of subjects: 100
Study 6605681 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg a day)
Number of subjects: 100
Study 6605681 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (750 mg a day)
Number of subjects: 100
Study 6605681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31369520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure management (target SBP 100< SBP ≤120 mmHg)
Number of subjects: 379
Study 31369520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure management
Number of subjects: 379
Study 31369520 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure management (target SBP 120< SBP ≤140 mmHg)
Number of subjects: 379
Study 31369520 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure management
Number of subjects: 379
Study 27573909 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute psychosocial stress (Trier Social Stress Test, TSST)
Number of subjects: 85
Study 27573909 — intervention group
Group type: COMPARATOR
Intervention: Control session (no stress)
Number of subjects: 85
Study 25819196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esmolol
Number of subjects: 412
Study 25819196 — intervention group
Group type: COMPARATOR
Intervention: Intravenous metoprolol
Number of subjects: 412
Study 24575769 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with bupivacaine 0.25%
Number of subjects: 197
Study 24575769 — intervention group
Group type: COMPARATOR
Intervention: Placebo group with sterile saline solution
Number of subjects: 197
Study 22971499 — intervention group
Group type: EXPERIMENTAL
Intervention: Target effect‐site remifentanil concentration of 1 ng/ml (R1 group)
Number of subjects: 102
Study 22971499 — intervention group
Group type: EXPERIMENTAL
Intervention: Target effect‐site remifentanil concentration of 2 ng/ml (R2 group)
Number of subjects: 102
Study 22971499 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 102
Study 19491611 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire regarding awareness of HPV
Number of subjects: 23000
Study 19491611 — intervention group
Group type: COMPARATOR
Intervention: Comparison with earlier study in Danish women
Number of subjects: 23000
Study 19491611 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher educational level and history of self-reported genital warts
Number of subjects: 23000
Study 19491611 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use and excellent self-rated health
Number of subjects: 23000
Study 19491611 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, lifetime number of sexual partners, smoking and drinking patterns
Number of subjects: 23000
Study 17330241 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 616
Study 17330241 — intervention group
Group type: COMPARATOR
Intervention: Regional anaesthesia
Number of subjects: 616
Study 17330241 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 616
Study 15371577 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic radiofrequency catheter ablation
Number of subjects: 60
Study 15371577 — intervention group
Group type: COMPARATOR
Intervention: No ablation (control group)
Number of subjects: 60
Study 11351147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal artificial bile infusion (80 mol% bile acids; 15 mol% phospholipids; 5 mol% cholesterol)
Number of subjects: 12
Study 11351147 — intervention group
Group type: COMPARATOR
Intervention: Intraduodenal saline infusion (placebo)
Number of subjects: 12
Study 11351147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal artificial bile infusion
Number of subjects: 12
Study 11351147 — intervention group
Group type: COMPARATOR
Intervention: Intraduodenal saline infusion
Number of subjects: 12
Study 9859958 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiron rgp 120 (SF-2) 15 or 50 microg; MicroGeneSys rgp 160 (IIIB) 40 or 320 microg; Genentech rgp120 (MN) 75 or 300 microg
Number of subjects: 0
Study 9859958 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant control (Alum or MF-59)
Number of subjects: 0
Study 9859958 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (various rgp vaccines)
Number of subjects: 0
Study 7542831 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0
Study 7542831 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 2684920 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 80
Study 2684920 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 80
Study 2684920 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 2684920 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation and music therapy (combined)
Number of subjects: 80
Study 1108622 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary potassium (48 mEq)
Number of subjects: 46
Study 1108622 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 46
Study 31835196 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-distancing prompt (writing or video)
Number of subjects: 0
Study 30612854 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 54
Study 28375709 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-free abdominal compression device (ACD) - N-Doe Pillow™
Number of subjects: 150
Study 28375709 — intervention group
Group type: COMPARATOR
Intervention: Manual pressure (Control)
Number of subjects: 150
Study 28375709 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-free abdominal compression device (ACD)
Number of subjects: 150
Study 24830423 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (Group A)
Number of subjects: 92
Study 24830423 — intervention group
Group type: COMPARATOR
Intervention: 0.45% saline (Group B)
Number of subjects: 92
Study 24830423 — intervention group
Group type: COMPARATOR
Intervention: 0.18% saline (Group C)
Number of subjects: 92
Study 24830423 — intervention group
Group type: COMPARATOR
Intervention: Hypotonic saline (Group B and C combined)
Number of subjects: 92
Study 24830423 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic saline (Group A)
Number of subjects: 92
Study 23838870 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-L polyethylene glycol electrolyte solution enriched in vitamin C
Number of subjects: 188
Study 23838870 — intervention group
Group type: COMPARATOR
Intervention: 4-L polyethylene glycol electrolyte solution
Number of subjects: 188
Study 21966835 — intervention group
Group type: EXPERIMENTAL
Intervention: American Diabetes Association 75 g curve
Number of subjects: 87
Study 21966835 — intervention group
Group type: EXPERIMENTAL
Intervention: American Diabetes Association 100 g curve
Number of subjects: 87
Study 21966835 — intervention group
Group type: COMPARATOR
Intervention: World Health Organization 75 g curve
Number of subjects: 87
Study 19903918 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning (20 hours per day)
Number of subjects: 342
Study 16616406 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced social support services
Number of subjects: 200
Study 16616406 — intervention group
Group type: COMPARATOR
Intervention: Support group (control)
Number of subjects: 200
Study 15579530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 2 g/kg monthly for 4 months
Number of subjects: 101
Study 15579530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 15579530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 101
Study 15579530 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG) and Placebo
Number of subjects: 101
Study 11520521 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 2658
Study 11520521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2658
Study 9421325 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin plus tobramycin
Number of subjects: 68
Study 9421325 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin plus tobramycin
Number of subjects: 68
Study 8489059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 10 micrograms
Number of subjects: 40
Study 8489059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 10 micrograms with 0.2 mg epinephrine
Number of subjects: 40
Study 8489059 — intervention group
Group type: COMPARATOR
Intervention: Control group (Intrathecal sufentanil without epinephrine)
Number of subjects: 40
Study 3337409 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted radiographs
Number of subjects: 83
Study 3337409 — intervention group
Group type: COMPARATOR
Intervention: Plain (unweighted) radiographs
Number of subjects: 83
Study 31562147 — intervention group
Group type: EXPERIMENTAL
Intervention: Edible taste film kit test
Number of subjects: 62
Study 31562147 — intervention group
Group type: COMPARATOR
Intervention: Taste solution test
Number of subjects: 62
Study 28509078 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU/week)
Number of subjects: 80
Study 25451430 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.5 mg/kg)
Number of subjects: 29
Study 23385548 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with piritramid intravenously by infusion pump
Number of subjects: 38
Study 23385548 — intervention group
Group type: COMPARATOR
Intervention: Standard pain management with oral non-steroidal analgesics
Number of subjects: 38
Study 23385548 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 38
Study 20850348 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion beginning at 25 μg/kg/min and morphine boluses (P)
Number of subjects: 145
Study 20850348 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl infusion beginning at 2 μg/kg/h and midazolam boluses (F)
Number of subjects: 145
Study 20850348 — intervention group
Group type: COMPARATOR
Intervention: Propofol and fentanyl infusions beginning at 25 μg/kg/min and 0.5 μg/kg/h (PF)
Number of subjects: 145
Study 18166166 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate spatial frequency (SF)
Number of subjects: 0
Study 18166166 — intervention group
Group type: EXPERIMENTAL
Intervention: High spatial frequency (SF)
Number of subjects: 0
Study 18166166 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright faces
Number of subjects: 0
Study 22015327 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive (OC) alone (ethinyl estradiol [EE] 0.035 mg + norethindrone [NET] 1 mg)
Number of subjects: 27
Study 22015327 — intervention group
Group type: EXPERIMENTAL
Intervention: OC + vicriviroc
Number of subjects: 27
Study 22015327 — intervention group
Group type: EXPERIMENTAL
Intervention: OC + ritonavir
Number of subjects: 27
Study 22015327 — intervention group
Group type: EXPERIMENTAL
Intervention: OC + vicriviroc + ritonavir
Number of subjects: 27
Study 22015327 — intervention group
Group type: COMPARATOR
Intervention: Placebo OC
Number of subjects: 27
Study 22015327 — intervention group
Group type: COMPARATOR
Intervention: OC alone
Number of subjects: 27
Study 22015327 — intervention group
Group type: EXPERIMENTAL
Intervention: vicriviroc + OC
Number of subjects: 27
Study 22015327 — intervention group
Group type: EXPERIMENTAL
Intervention: ritonavir + OC
Number of subjects: 27
Study 22015327 — intervention group
Group type: EXPERIMENTAL
Intervention: vicriviroc + ritonavir + OC
Number of subjects: 27
Study 22015327 — intervention group
Group type: COMPARATOR
Intervention: placebo OC
Number of subjects: 27
Study 16105178 — intervention group
Group type: EXPERIMENTAL
Intervention: Applications with at least one error
Number of subjects: 493
Study 16105178 — intervention group
Group type: EXPERIMENTAL
Intervention: Applications excluding 'benign' errors
Number of subjects: 493
Study 16105178 — intervention group
Group type: EXPERIMENTAL
Intervention: Publications in applications
Number of subjects: 493
Study 16105178 — intervention group
Group type: EXPERIMENTAL
Intervention: Claims of advanced degrees
Number of subjects: 493
Study 16105178 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater reliability of evaluations
Number of subjects: 493
Study 11876511 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate (400 mg once daily)
Number of subjects: 69
Study 11876511 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil (600 mg twice daily)
Number of subjects: 69
Study 11876511 — intervention group
Group type: EXPERIMENTAL
Intervention: fenofibrate (200 mg once daily)
Number of subjects: 69
Study 11876511 — intervention group
Group type: EXPERIMENTAL
Intervention: fibrates (general)
Number of subjects: 69
Study 9842605 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-min. run
Number of subjects: 32
Study 9842605 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mile run
Number of subjects: 32
Study 9842605 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-m progressive shuttle run
Number of subjects: 32
Study 9842605 — intervention group
Group type: EXPERIMENTAL
Intervention: treadmill jogging test
Number of subjects: 32
Study 7813537 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg, 0.4 g/kg body weight per day for 5 consecutive days, followed by the same dose once every 2 weeks for 3 months)
Number of subjects: 15
Study 7813537 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 15
Study 2776469 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg flurbiprofen twice daily
Number of subjects: 50
Study 2776469 — intervention group
Group type: COMPARATOR
Intervention: 500 mg diflunisal twice daily
Number of subjects: 50
Study 791433 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 20
Study 791433 — intervention group
Group type: COMPARATOR
Intervention: Dominant/Nondominant Unilateral ECT
Number of subjects: 20
Study 31651593 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based vergence/accommodative therapy
Number of subjects: 311
Study 31651593 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 311
Study 29952617 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively framed message about peers who do use PBS
Number of subjects: 89
Study 29952617 — intervention group
Group type: COMPARATOR
Intervention: Negatively framed message about peers who do not use PBS
Number of subjects: 89
Study 27129980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based telephone follow-up
Number of subjects: 201
Study 27129980 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 201
Study 25207898 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cantharidinate/vitamin B6 + GP regimen (30 ml cantharidinate/vitamin B6 for four 21-day cycles)
Number of subjects: 86
Study 25207898 — intervention group
Group type: COMPARATOR
Intervention: Regular GP regimen (for four 21-day cycles)
Number of subjects: 86